TipRanks
Advertisement
Advertisement

DE:P0F Stock Latest News

Egetis Therapeutics Adjusts Share Composition After Employee Stock Option Exercise
Company AnnouncementsEgetis Therapeutics Adjusts Share Composition After Employee Stock Option Exercise
7d ago
Egetis Wins First U.S. FDA Approval for MCT8 Deficiency Therapy EMCITATE
PremiumCompany Announcements
Egetis Wins First U.S. FDA Approval for MCT8 Deficiency Therapy EMCITATE
9d ago
Egetis to Present New Emcitate Data at Major European Endocrinology Meetings
PremiumCompany Announcements
Egetis to Present New Emcitate Data at Major European Endocrinology Meetings
1M ago
Egetis Steps Up Investor Outreach Ahead of Key FDA Decision
PremiumCompany Announcements
Egetis Steps Up Investor Outreach Ahead of Key FDA Decision
1M ago
Egetis Wins Japanese Orphan Status for Emcitate in Rare MCT8 Disorder
PremiumCompany Announcements
Egetis Wins Japanese Orphan Status for Emcitate in Rare MCT8 Disorder
1M ago
Egetis Bolsters Finances and IP as Emcitate Nears Key FDA Decision
PremiumCompany AnnouncementsEgetis Bolsters Finances and IP as Emcitate Nears Key FDA Decision
2M ago
Is P0F a Buy, Before Earnings?
Premium
Pre-Earnings
Is P0F a Buy, Before Earnings?
2M ago
Egetis sets Q2 2026 results date as Emcitate nears key FDA decision
Premium
Company Announcements
Egetis sets Q2 2026 results date as Emcitate nears key FDA decision
2M ago
Egetis Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Egetis Therapeutics initiated with an Overweight at Cantor Fitzgerald
3M ago
Egetis Backs National Lifetime Re-Air of MCT8 Deficiency Awareness Episode
PremiumCompany Announcements
Egetis Backs National Lifetime Re-Air of MCT8 Deficiency Awareness Episode
4M ago
Egetis Converts Class C Shares After Option Exercise, Boosting Voting Rights
PremiumCompany Announcements
Egetis Converts Class C Shares After Option Exercise, Boosting Voting Rights
4M ago
Egetis highlights MCT8 healthcare costs as Emcitate nears key U.S. review
PremiumCompany Announcements
Egetis highlights MCT8 healthcare costs as Emcitate nears key U.S. review
5M ago
Egetis Executives Exercise Stock Options and Sell Shares for Tax and Personal Reasons
PremiumCompany AnnouncementsEgetis Executives Exercise Stock Options and Sell Shares for Tax and Personal Reasons
5M ago
Egetis Targets Global Specialist Community With 2026 Conference Push
Premium
Company Announcements
Egetis Targets Global Specialist Community With 2026 Conference Push
5M ago
Egetis Gains Key U.S. Patent Protection for Emcitate in MCT8 Deficiency
Premium
Company Announcements
Egetis Gains Key U.S. Patent Protection for Emcitate in MCT8 Deficiency
5M ago
Egetis Uses Pediatric Endocrine Meeting to Build Momentum for Emcitate
PremiumCompany Announcements
Egetis Uses Pediatric Endocrine Meeting to Build Momentum for Emcitate
5M ago
Egetis boosts share capital as it advances rare-disease drug portfolio
PremiumCompany Announcements
Egetis boosts share capital as it advances rare-disease drug portfolio
5M ago
Egetis Wins FDA Priority Review for Emcitate as EU Launch Gathers Pace
PremiumCompany Announcements
Egetis Wins FDA Priority Review for Emcitate as EU Launch Gathers Pace
5M ago
Egetis Sets Q1 2026 Report Date as Emcitate Nears Key U.S. Milestone
PremiumCompany Announcements
Egetis Sets Q1 2026 Report Date as Emcitate Nears Key U.S. Milestone
6M ago
Egetis Raises SEK 350 Million to Drive Emcitate Toward U.S. Approval and Launch
PremiumCompany AnnouncementsEgetis Raises SEK 350 Million to Drive Emcitate Toward U.S. Approval and Launch
6M ago
Egetis Therapeutics to Raise SEK 350 Million in Directed Share Issue to Fund Emcitate US Launch
Premium
Company Announcements
Egetis Therapeutics to Raise SEK 350 Million in Directed Share Issue to Fund Emcitate US Launch
6M ago
Egetis Therapeutics AGM Backs New Board, Incentive Schemes and Capital Mandate
Premium
Company Announcements
Egetis Therapeutics AGM Backs New Board, Incentive Schemes and Capital Mandate
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >